Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
By SquaredTown on April 6, 2026
New data underscoring the potential of ATNM-400 as a first-in-class Ac-225 radioconjugate with broad pan-tumor efficacy across multiple solid tumor models Actimab-A demonstrates mutation-agnostic efficacy and a novel mechanism that enhances response to standard AML therapies Multiple data...